Can a diabetes drug tame dangerous blood sugar drops in a rare metabolic disorder?
NCT ID NCT07739394
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This study looks at whether diazoxide, a drug that reduces insulin release, can help children with type 1 glycogenosis maintain steadier blood sugar levels. Type 1 glycogenosis is a rare inherited condition where the body cannot properly release glucose from stored glycogen, leading to dangerously low blood sugar. The trial will compare metabolic control—specifically blood sugar and lactic acid levels—in children who receive diazoxide versus those who do not.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- diazoxide
- What this could lead to
- If effective, diazoxide could offer a new way to stabilize blood sugar in children with type 1 glycogenosis, potentially reducing the need for frequent feeding.
- What could go wrong
- This is a small study, and results may not apply to all patients. Diazoxide can have side effects, and its benefit over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLYCOGEN STORAGE DISEASE TYPE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.